These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34780866)

  • 1. Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy.
    Krittanawong C; Khawaja M; Rosenson RS; Amos CI; Nambi V; Lavie CJ; Virani SS
    Curr Probl Cardiol; 2022 Jul; 47(7):101043. PubMed ID: 34780866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo.
    Suchowerska AK; Stokman G; Palmer JT; Coghlan PA; Pieterman EJ; Keijzer N; Lambert G; Chemello K; Jaafar AK; Parmar J; Yan L; Tong Y; Mu L; Princen HMG; Bonnar J; Evison BJ
    J Lipid Res; 2022 Nov; 63(11):100293. PubMed ID: 36209894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment.
    Sliz E; Kettunen J; Holmes MV; Williams CO; Boachie C; Wang Q; Männikkö M; Sebert S; Walters R; Lin K; Millwood IY; Clarke R; Li L; Rankin N; Welsh P; Delles C; Jukema JW; Trompet S; Ford I; Perola M; Salomaa V; Järvelin MR; Chen Z; Lawlor DA; Ala-Korpela M; Danesh J; Davey Smith G; Sattar N; Butterworth A; Würtz P
    Circulation; 2018 Nov; 138(22):2499-2512. PubMed ID: 30524137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition.
    Ouyang M; Li C; Hu D; Peng D; Yu B
    Clin Chim Acta; 2023 Jan; 538():113-123. PubMed ID: 36403664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors.
    Blanchard V; Chemello K; Hollstein T; Hong-Fong CC; Schumann F; Grenkowitz T; Nativel B; Coassin S; Croyal M; Kassner U; Lamina C; Steinhagen-Thiessen E; Lambert G
    Cardiovasc Res; 2022 Jul; 118(9):2103-2111. PubMed ID: 34314498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies.
    Mahmood T; Minnier J; Ito MK; Li QH; Koren A; Kam IW; Fazio S; Shapiro MD
    Eur J Prev Cardiol; 2021 Jul; 28(8):816-822. PubMed ID: 34298554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
    Warden BA; Duell PB
    J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies.
    Oleaga C; Shapiro MD; Hay J; Mueller PA; Miles J; Huang C; Friz E; Tavori H; Toth PP; Wójcik C; Warden BA; Purnell JQ; Duell PB; Pamir N; Fazio S
    J Am Coll Cardiol; 2021 Oct; 78(14):1437-1449. PubMed ID: 34593126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 Biology and Its Role in Atherothrombosis.
    Barale C; Melchionda E; Morotti A; Russo I
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
    Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
    J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
    Ference BA; Robinson JG; Brook RD; Catapano AL; Chapman MJ; Neff DR; Voros S; Giugliano RP; Davey Smith G; Fazio S; Sabatine MS
    N Engl J Med; 2016 Dec; 375(22):2144-2153. PubMed ID: 27959767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy.
    Warden BA; Minnier J; Watts GF; Fazio S; Shapiro MD
    J Clin Lipidol; 2019; 13(4):580-585. PubMed ID: 31130489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol-Lowering Agents.
    Rosenson RS; Hegele RA; Koenig W
    Circ Res; 2019 Feb; 124(3):364-385. PubMed ID: 30702994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].
    Pedro-Botet J; Badimón L
    Clin Investig Arterioscler; 2016 May; 28 Suppl 2():3-8. PubMed ID: 27888903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 targets important for lipid metabolism.
    Schulz R; Schlüter KD
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):2-11. PubMed ID: 28176216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke.
    De Marchis GM; Dittrich TD; Malik R; Zietz AV; Kriemler LF; Ference BA; Dichgans M; Georgakis MK
    Atherosclerosis; 2022 Nov; 361():41-46. PubMed ID: 36244797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.